Cargando…

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation

Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through the adminis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albert, Brice J., Niu, Austin, Ramani, Rashmi, Marshall, Garland R., Wender, Paul A., Williams, Robert M., Ratner, Lee, Barnes, Alexander B., Kyei, George B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547048/ https://www.ncbi.nlm.nih.gov/pubmed/28785069 http://dx.doi.org/10.1038/s41598-017-07814-4

Ejemplares similares

Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency
por: Heffern, Elleard FW, et al.
Publicado: (2019)

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication
por: Marsden, Matthew D., et al.
Publicado: (2017)

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016)

Synthesis of a des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core
por: Kraft, Matthew B., et al.
Publicado: (2014)

Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism
por: Díaz, Laura, et al.
Publicado: (2015)

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold
por: Wender, Paul A., et al.
Publicado: (2014)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs
por: Wender, Paul A., et al.
Publicado: (2014)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

Synthesis of seco-B-Ring Bryostatin Analogue WN-1 via C–C Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties
por: Andrews, Ian P., et al.
Publicado: (2014)

Bryostatin-1 vs. TPPB: Dose-Dependent APP Processing and PKC-α, -δ, and -ε Isoform Activation in SH-SY5Y Neuronal Cells
por: Yi, P., et al.
Publicado: (2012)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy
por: Wang, Ze, et al.
Publicado: (2023)

Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
por: Kyei, George B., et al.
Publicado: (2018)

Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
por: Mehla, Rajeev, et al.
Publicado: (2010)

Cytoplasmic Dynein Antagonists with Improved Potency and Isoform Selectivity
por: See, Stephanie K., et al.
Publicado: (2015)

Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships
por: Kedei, Noemi, et al.
Publicado: (2015)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

The Effect of Vicinal Difluorination on the Conformation and Potency of Histone Deacetylase Inhibitors
por: Ariawan, A. Daryl, et al.
Publicado: (2021)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

Synthetic Kavalactone Analogues with Increased Potency and Selective Anthelmintic Activity against Larvae of Haemonchus contortus In Vitro
por: Herath, H.M.P. Dilrukshi, et al.
Publicado: (2020)

Peptide Arrays Identify Isoform-Selective Substrates for Profiling Endogenous Lysine Deacetylase Activity
por: Gurard-Levin, Zachary A., et al.
Publicado: (2010)

SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation
por: Sarikhani, Mohsen, et al.
Publicado: (2018)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
por: Cogram, Patricia, et al.
Publicado: (2020)

Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
por: Prendiville, J., et al.
Publicado: (1994)

Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
por: Reuse, Sophie, et al.
Publicado: (2009)

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
por: Demyanenko, Svetlana, et al.
Publicado: (2021)

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction
por: Beshore, Douglas C., et al.
Publicado: (2021)

Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues
por: Chang, Xiaoqing, et al.
Publicado: (2022)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996)

Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors that Potently Reactivate Latent HIV
por: Curreli, Francesca, et al.
Publicado: (2020)

Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model.
por: Richter, A. M., et al.
Publicado: (1991)

Thiopurines Analogues with Additional Ring: Synthesis, Spectroscopic Properties, and Anticancer Potency
por: Krancewicz, Katarzyna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ukoh1ihoba1ve4du6oeujaa1lm